Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplant after Brentuximab Vedotin in Patients with Hodgkin Lymphoma Relapsed after Autologous Transplant

Francesco Zallio, MD, Alessandro Busca, MD, Nicola Mordini, Maria jose Fornaro, Benedetto Bruno, MD PhD, Gioacchino Catania, Flavia Salvi, MD, Guido Parvis, Marco Ladetto, Massimo Pini, MD

Blood (2014) 124 (21): 5943.

https://doi.org/10.1182/blood.V124.21.5943.5943

Published: 2014

Journal Articles

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Blood (2013) 122 (21): 551.

https://doi.org/10.1182/blood.V122.21.551.551

Published: 2013

Journal Articles

Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial

Blood (2012) 120 (21): 1984.

https://doi.org/10.1182/blood.V120.21.1984.1984

Published: 2012

Journal Articles

Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial

Blood (2012) 120 (21): 550.

https://doi.org/10.1182/blood.V120.21.550.550

Published: 2012

Journal Articles

PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL)

Blood (2012) 120 (21): 787.

https://doi.org/10.1182/blood.V120.21.787.787

Published: 2012

Journal Articles

Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

Blood (2011) 118 (21): 777.

https://doi.org/10.1182/blood.V118.21.777.777

Published: 2011

Journal Articles

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Marco Ruella, MD, Andrea Filippi, MD, Anna DI Russo, MD, Daniele Caracciolo, MD, Paola Matteucci, MD, Michele Magni, MD, Massimo Di Nicola, MD, Umberto Ricardi, MD, Vittorio Montefusco, MD, Guido Parvis, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD, Liliana Devizzi, MD

Blood (2011) 118 (21): 3699.

https://doi.org/10.1182/blood.V118.21.3699.3699

Published: 2011

Journal Articles

Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis

Blood (2011) 118 (21): 1606.

https://doi.org/10.1182/blood.V118.21.1606.1606

Published: 2011

Journal Articles

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

Blood (2009) 114 (22): 1706.

https://doi.org/10.1182/blood.V114.22.1706.1706

Published: 2009

Journal Articles

A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.

Blood (2009) 114 (22): 882.

https://doi.org/10.1182/blood.V114.22.882.882

Published: 2009

Journal Articles

Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).

Blood (2009) 114 (22): 2316.

https://doi.org/10.1182/blood.V114.22.2316.2316

Published: 2009

Journal Articles

Male Gender, Quality of Grafted Cells, Advanced Age, Rituximab and Radiotherapy Are the Main Factors That Variously Influence the Occurrence of Secondary Malignancies Following High-Dose Therapy and Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in 1,347 Lymphoma Patients.

Blood (2009) 114 (22): 519.

https://doi.org/10.1182/blood.V114.22.519.519

Published: 2009

Journal Articles

Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

Blood (2008) 112 (11): 834.

https://doi.org/10.1182/blood.V112.11.834.834

Published: 2008

Journal Articles

Safety and Tolerability of Intrathecal Liposomal Cytarabine during CNS Prophylaxis in Patients with Non Hodgkin Lymphoma and Acute Lymphoblastic Leukemia.

Luciana Annino, MD, Barbara Anaclerico, MD, Giulia Benevolo, MD, Nicola Cascavilla, MD, Michele Cimminiello, MD, Matteo Dell’Olio, MD, Alfredo Gagliardi, MD, Giulio Giordano, MD, Eustachio Miraglia, MD, Maurizio Musso, MD, Guido Parvis, MD, Silvia Piano, MD, Chiara Pilatrino, MD, Renato Scalone, MD, Adriano Venditti, MD, Daniela Venditti, MD, Umberto Vitolo, MD, Sergio Storti, MD

Blood (2007) 110 (11): 4460.

https://doi.org/10.1182/blood.V110.11.4460.4460

Published: 2007

Journal Articles

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following Intensive Therapy and Autograft Correlates with the Type of Cells Grafted: A Survey on 1,347 Lymphoma Patients Receiving the High-Dose Sequential (HDS) Program.

Manuela Zanni, MD, Michele Magni, MD, Alessandro Rambaldi, MD, Fabio Benedetti, MD, Roberto Passera, PhD, Caterina Patti, MD, Guido Parvis, MD, Fabio Ciceri, MD, Andrea Gallamini, MD, Sergio Cortelazzo, MD, Ignazio Majolino, MD, Salvo Mirto, MD, Paolo Corradini, MD, Mario Boccadoro, MD, Giuseppe Saglio, MD, Giovanni Pizzolo, MD, Tiziano Barbui, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD

Blood (2007) 110 (11): 1083.

https://doi.org/10.1182/blood.V110.11.1083.1083

Published: 2007

Journal Articles

Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638)

Blood (2007) 110 (11): 1278.

https://doi.org/10.1182/blood.V110.11.1278.1278

Published: 2007

Journal Articles

Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma

Sergio Cortelazzo, MD, Michele Magni, MD, Corrado Tarella, MD, Michael Mian, MD, Atto Billio, MD, Andrea Rossi, MD, Maddalena Marchesi, MD, Andrea Gallamini, MD, Paolo Corradini, MD, Fabio Ciceri, MD, Guido Parvis, MD, Ignazio Majolino, MD, Caterina Patti, MD, Salvo Mirto, MD, Fabio Benedetti, MD, Giovanni Pizzolo, MD, Alessandro M. Gianni, MD, Alessandro Rambaldi, MD

Blood (2007) 110 (11): 1282.

https://doi.org/10.1182/blood.V110.11.1282.1282

Published: 2007

Journal Articles

JAK2V617F Mutation in Leukaemic Transformation of Philadelphia Negative Chronic Myeloproliferative Disorders.

Davide Rossi, MD, Clara Deambrogi, PhD, Daniela Capello, PhD, Michaela Cerri, PhD, Monia Lunghi, MD, Lorenzo De Paoli, MD, Guido Parvis, MD, Giuseppe Saglio, MD, Gianluca Gaidano, MD,PhD, Daniela Cilloni, MD

Blood (2006) 108 (11): 3605.

https://doi.org/10.1182/blood.V108.11.3605.3605

Published: 2006

Journal Articles

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)

Alessandro M. Gianni, Michele Magni, Maurizio Martelli, Massimo Di Nicola, Carmelo Carlo-Stella, Silvana Pilotti, Alessandro Rambaldi, Sergio Cortelazzo, Caterina Patti, Guido Parvis, Fabio Benedetti, Saveria Capria, Paolo Corradini, Corrado Tarella, Tiziano Barbui

Blood (2003) 102 (2): 749–755.

https://doi.org/10.1182/blood-2002-08-2476

Published: 2003

NARROW

Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplant after Brentuximab Vedotin in Patients with Hodgkin Lymphoma Relapsed after Autologous Transplant

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial

Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial

PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL)

Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).

Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

Safety and Tolerability of Intrathecal Liposomal Cytarabine during CNS Prophylaxis in Patients with Non Hodgkin Lymphoma and Acute Lymphoblastic Leukemia.

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following Intensive Therapy and Autograft Correlates with the Type of Cells Grafted: A Survey on 1,347 Lymphoma Patients Receiving the High-Dose Sequential (HDS) Program.

Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638)

Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma

JAK2V617F Mutation in Leukaemic Transformation of Philadelphia Negative Chronic Myeloproliferative Disorders.

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only